Evidence map›Paper›PMID 29212713›Full record

ArticleScience translational medicine2017

A degradation fragment of type X collagen is a real-time marker for bone growth velocity.

Ryan F Coghlan, Jon A Oberdorf, Susan Sienko, Michael D Aiona, Bruce A Boston, Kara J Connelly, Chelsea Bahney, Jeremie LaRouche, Sarah M Almubarak, Daniel T Coleman and 4 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04914507 (A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering), which is not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04914507 narecruitingnot on this mapstarted 2021, after this paper: background citation

A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering

TypeinterventionalSponsorPediatric Spine FoundationRan2021 to 2029Enrolled106ConditionsScoliosis IdiopathicArmsAnterior Vertebral Body Tethering
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Fracture nonunions.OTA international : the open access journal of orthopaedic trauma · 2025
    Article
  8. C-type natriuretic peptide and collagen X marker are aberrant in skeletal dysplasias.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Article
  9. Observational
  10. Regenerative biomaterials · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Transient neonatal shoulder paralysis causes early osteoarthritis in a mouse model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
  20. Collagen X Biomarker (CXM), Linear Growth, and Bone Development in a Vitamin D Intervention Study in Infants.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Ryan F CoghlanResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-6318-9870
Jon A OberdorfResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-0589-7115
Susan SienkoResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-6095-6034
Michael D AionaResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-1320-2950
Bruce A BostonDepartment of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0001-9808-2275
Kara J ConnellyDepartment of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-5598-388X
Chelsea BahneyDepartment of Orthopedic Surgery, University of California Medical School, San Francisco, CA 94111, USA.ORCID http://orcid.org/0000-0001-9808-8888
Jeremie LaRoucheDepartment of Orthopedic Surgery, University of California Medical School, San Francisco, CA 94111, USA.
Sarah M AlmubarakDepartment of Orthopedic Surgery, University of California Medical School, San Francisco, CA 94111, USA.ORCID http://orcid.org/0000-0002-3881-4136
Daniel T ColemanGraduate School of Social Service, Fordham University, Lincoln Center, New York, NY 10023, USA.ORCID http://orcid.org/0000-0002-0043-3741
Irute GirkontaiteDepartment of Immunology, State Research Institute, Vilnius University, Vilnius, Lithuania.ORCID http://orcid.org/0000-0002-3659-3202
Klaus von der MarkFreidrich-Alexander University, Erlangen, Germany.
Gregory P LunstrumResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA.ORCID http://orcid.org/0000-0002-1865-7321
William A HortonResearch Center, Shriners Hospitals for Children, Portland, OR 97239, USA. wah@shcc.org.ORCID http://orcid.org/0000-0002-5742-7377
Oregon Health & Science University · USShriners Hospitals for Children - Portland · USUniversity of California San Francisco Medical Center · USFordham University · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.

Indexed as

AdultAnimalsBone DevelopmentCollagen Type XEnzyme-Linked Immunosorbent AssayFemaleFracture HealingHumansMaleMiceYoung AdultCollagen Type X

Identifiers

PMID29212713
PMCPMC6516194
OpenAlexW2774426883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.